With Trial Approval, Medtronic Aims For Symplicity RF Catheter Launch In 2014
This article was originally published in The Gray Sheet
Executive Summary
With conditional FDA approval for its pivotal trial in hand, Medtronic says it is on track to launch its Symplicity renal nerve ablation catheter system for drug-resistant hypertension in the U.S. in 2014.
You may also be interested in...
Cardio Catch-Up: Medtronic Still Has Work To Do On RDN After FDA Advisory Panel
FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one of the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.